Homeapotherapy research desk Find my starting point

Product fact sheet

CeraVe Eczema Relief Creamy Oil

CeraVe Eczema Relief Creamy Oil combines 1% colloidal oatmeal with ceramides and an oil-rich fragrance-free vehicle for barrier-supportive eczema care.

Eczema treatment guideSee this product beside other eczema-care formulations and the treatment ladder it fits into. Compare in context →
Desk researchedFacts checked 2026-08-11

Creamy-oil vehicle with 1% colloidal oatmeal plus ceramides and humectants; useful as a vehicle-versus-active comparison record.

Fit signals

comparing cream versus oil-like vehicles, checking colloidal-oatmeal concentration

Potential constraints

comparative efficacy claims, assuming plant oils suit every skin type

Key tradeoff: Ingredient richness is a formula fact, not evidence that it will outperform a simpler cream.

This is a factual fit-and-tradeoff summary, not a product recommendation. Formula, device and brand claims remain manufacturer claims unless the cited source is explicitly regulatory or independent testing.

1% colloidal oatmeal in an oil-rich vehicle

CeraVe Eczema Relief Creamy Oil combines a 1% colloidal-oatmeal OTC skin-protectant active with a richer, oil-containing leave-on vehicle. The manufacturer also lists ceramides and humectant ingredients and describes the formula as fragrance-free. The active concentration can therefore be compared alongside the richer vehicle, which differs from a conventional cream or lotion in texture and emollience.

How to compare it

Vehicle matters in eczema care because texture, occlusiveness and ease of repeated application can influence whether a product fits a routine. Plant oils and a longer supporting ingredient list do not establish stronger eczema control. They are formulation characteristics that may matter for skin feel, sensitivity history and preference.

This product should also be separated from OTC pramoxine anti-itch medicines and prescription anti-inflammatory treatments. Sharing an eczema-related label does not make those categories interchangeable.

Evidence and safety context

Follow the current Drug Facts and stop or seek advice for significant irritation, worsening disease or symptoms that do not respond as expected. The 1% colloidal-oatmeal label supports the product’s OTC skin-protectant role; it does not make the product equivalent to prescription anti-inflammatory treatment.

See the eczema treatment hub for the broader treatment ladder.

Formula facts

Ingredients, actives and label details

Product form
Creamy oil
Basis: Manufacturer published Source: CeraVe Eczema Relief Creamy Oil — official product information
OTC active
Colloidal oatmeal
Basis: Manufacturer published Source: CeraVe Eczema Relief Creamy Oil — official product information
Active concentration
1%
Basis: Manufacturer published Source: CeraVe Eczema Relief Creamy Oil — official product information
Formula profile
Ceramides, glycerin, niacinamide, plant oils and hydrolyzed hyaluronic acid; fragrance-free
Basis: Manufacturer published Source: CeraVe Eczema Relief Creamy Oil — official product information
Label scope
Skin protectant for minor irritation and itching due to eczema
Basis: Manufacturer published Source: CeraVe Eczema Relief Creamy Oil — official product information

Source labels preserve provenance. Manufacturer specifications, ingredient lists and performance claims are not treated as independent clinical evidence; regulatory records and independent measurements are identified separately when available.

Safety first

What should make you slow down?

Use current Drug Facts and stop or seek advice for significant irritation or worsening eczema.

Where to buy

Current tracked merchants

Commerce note: merchant economics never enter our editorial score. Affiliate links are identified as (paid link) and use sponsored-link markup.

No merchant destination is currently tracked for this product.

Source trail

Primary documents and supporting evidence

  1. CeraVe Eczema Relief Creamy Oil — official product informationCeraVe · Manufacturer · retrieved 2026-08-11